Figure 1. Roya Lisboa, RN, holding a SorbaView bandage (Centurion Medical Products).
Small innovations can make a big difference. It’s a recurrent theme in interventional cardiology. Small changes or new application of a common piece or equipment, supply, or method can make a difference in your lab.1,2
Figure 2. The Tegederm bandage being applied to the radial sheath. Lower right, view of draping for our radial procedures using the Armen glove method.3
Last week, Roya Lisboa (Figure 1), one of our super cath lab nurses, handed me an IV bandage to secure the radial sheath. I’d been complaining, as many of my colleagues have reported, that the usual Tegederm clear plastic bandage (Figure 2) with a slit, holds the sheath in place for most routine cases but fails for longer procedures, especially when blood gets under the plastic.
Figure 3. The SorbaView bandage. Left, adhesive side before removal of paper covers; middle, front side of SorbaView bandage; right, different size SorbaView bandage showing clear window and a port to see hub of catheter/sheath/IV. Blue lines are reinforcing tapes incorporated into bandage.
The SorbaView bandage (Centurion Medical Products) (Figure 3) has a clear window and fabric adhesive border with a locking piece of adhesive added after the bandage is placed. It is usually used to protect IV needles and catheters. The fabric border prevents blood from leaking into the puncture area. To secure the radial sheath, we made sure to attach the fabric adhesive to the hub of the sheath with the side arm passing under the adhesive and the locking patch over the side arm (Figure 4).
Figure 4A. Application of the SorbaView bandage to the radial sheath. The fabric tape is adhered to the sheath hub. The side arm is looped to the top of the arm and covered by the SorbaView clear window and fabric border.
I asked my expert colleagues what they used for securing their radial sheaths and the answers were interesting:
Most respondents used Tegederm, but complained that its securing function is short-lived and if blood gets under it, it is a mess and stops working. This usually occurs involving a long case with multiple catheter exchanges.
Figure 4B. Final SorbaView application with locking patch holding the side arm as it exits the sheath. The bandage stayed dry for the entire procedure and was easy to remove.
Several operators use long sheaths with no securing technique needed.
Several operators use a suture if the sheath needs to be secured for long case.
One European operator doesn’t use sheaths and goes sheathless for his procedures.
Figure 5. Three sheath-securing devices. Left, Statlock (Maquet); top right, StayFIX (Merit Medical); bottom right, StatLock arterial ultra-stabilization device (Bard Access Systems).
Several other devices available in our lab were investigated but none seemed suitable (Figure 5). While only a small change in our radial technique, the use of a new securing method may be a big advance for the procedure. It’s always a good idea to keep your eyes open in the cath lab.
References
Kern MJ. New ideas from cardiac cath lab staff. Cath Lab Digest. 2008 Mar; 16(4). Available online at https://www.cathlabdigest.com/articles/New-Ideas-Cardiac-Cath-Lab-Staff. Accessed Dec 12, 2017.
Kern MJ. Small innovations can make a big difference: the role of staff initiatives to drive efficiency in the cath lab. Cath Lab Digest. 2017 Feb; 25(2). Available online at https://www.cathlabdigest.com/article/Small-Innovations-Can-Make-Big-Difference-Role-Staff-Initiatives-Drive-Efficiency-Cath-Lab. Accessed December 12, 2017.
Kern MJ. The Armen glove for radial access prep — a better way. Cath Lab Digest. 2010 May; 18(5). Available online at https://www.cathlabdigest.com/articles/The-Armen-Glove-Radial-Access-Prep-%E2%80%93-A-Better-Way. Accessed December 12, 2017.
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Eli Lilly and Company announced positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine designed to durably turn off the PCSK9 gene in the liver and lower blood low-density lipoprotein...
Boston, MA – NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
Boston, MA – NodThera, a clinical-stage NLRP3 company developing a portfolio of potentially best-in-class brain-penetrant oral NLRP3 inhibitors to address inflammatory drivers of cardiometabolic and neurologic diseases, announced the...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
BOSTON--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, announced the enrollment of the first patient in its first-in-human (FIH) study for...
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
DEEPER CORONARY is a first-in-human pilot study designed to evaluate the short-term safety of the investigational coronary Spur Elute System as a primary treatment for coronary ISR.
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
SANTA ROSA, Calif.--(BUSINESS WIRE)--Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, today announced the acquisition of the Pounce™...
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease.
